ClinConnect ClinConnect Logo
Search / Trial NCT05480644

Circulating Biomarkers Repository in Adults Diagnosed With Primary and Metastatic Brain Tumors

Launched by DUKE UNIVERSITY · Jul 27, 2022

Trial Information

Current as of July 25, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is focused on collecting blood samples from adults diagnosed with primary brain tumors (tumors that start in the brain) or metastatic brain tumors (tumors that have spread to the brain from other parts of the body). The goal is to create a valuable resource, known as a repository, that can help researchers better understand these types of tumors and improve future treatments. The study is currently looking for participants, and anyone aged 18 and older who has been confirmed to have one of these brain tumors may be eligible to join.

If you decide to participate, you will simply provide a blood sample during your visit to the Duke Cancer Center’s Department of Radiation Oncology. There are no specific exclusions based on health conditions, so if you meet the diagnosis criteria, you can join. This trial is an important step in advancing our knowledge about brain tumors and could potentially lead to better care for patients in the future.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Have a confirmed diagnosis of primary or metastatic brain tumor (histology or imaging as appropriate)
  • Exclusion Criteria:
  • None

About Duke University

Duke University, a leading academic and research institution located in Durham, North Carolina, is renowned for its commitment to advancing healthcare through innovative clinical research. With a strong emphasis on interdisciplinary collaboration, Duke conducts a wide array of clinical trials aimed at developing cutting-edge therapies and improving patient outcomes across various medical fields. The university's Clinical Research Institute provides comprehensive support for trial design, implementation, and regulatory compliance, ensuring that all research adheres to the highest ethical and scientific standards. Duke’s dedication to translating research findings into effective clinical practices underscores its role as a pivotal contributor to the global medical community.

Locations

Durham, North Carolina, United States

Patients applied

0 patients applied

Trial Officials

Scott Floyd, MD PhD

Principal Investigator

Duke University Health System (DUHS)

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials